Diagnostic radiopharmaceuticals
This part of the company develops and supplies radioactive imaging agents that help doctors locate and track cancer in the body, especially through PET scans.
Customers and revenue model
C
Clarity Pharmaceuticals Ltd
ASX:CU6
Clarity Pharmaceuticals Ltd
ASX:CU6
Price on Oct 14:
1.825
AUD
Market Cap:
AU$680.9m
Prices of ASX stocks are not being updated. The latest CU6 price on Alpha Spread is from Oct 14, 2026. Financials, forecasts and intrinsic value keep updating.
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
AU |
|
Banca Mediolanum SpA
MIL:BMED
|
IT |
|
M
|
Medipost Co Ltd
KOSDAQ:078160
|
KR |
|
H
|
Hang Lung Group Ltd
HKEX:10
|
HK |
|
M
|
MONY Group PLC
OTC:MNSKY
|
UK |
|
T
|
Thai Airways International PCL
SET:THAI
|
TH |
|
P
|
Petrus Resources Ltd
TSX:PRQ
|
CA |
|
M
|
Mitie Group PLC
OTC:MITFY
|
UK |
|
K
|
Kaspi.kz AO
NASDAQ:KSPI
|
KZ |
|
Wizz Air Holdings PLC
LSE:WIZZ
|
HU |
|
Cobram Estate Olives Ltd
ASX:CBO
|
AU |
Company Overview
Business Description
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Headquarters
- Australia AU
- IPO date
- Aug 25, 2021
Clarity Pharmaceuticals is a radiopharmaceutical company that develops drugs used in medical imaging and cancer treatment. Its main idea is to attach copper-based radioactive isotopes to targeting molecules so doctors can see tumors more clearly on scans or deliver radiation directly to cancer cells.
The company does not sell mass-market medicines. It works with hospitals, nuclear medicine specialists, and clinical partners to develop and commercialize diagnostic and therapeutic products, especially for oncology. Its products are designed to be made, shipped, and used through the medical imaging and treatment workflow rather than through regular pharmacy channels.
Clarity makes money by advancing these products through development, then selling or licensing approved radiopharmaceuticals and related services into the healthcare market. What makes its business model distinct is its focus on copper radioisotopes, which can be used for both imaging and therapy, giving it a tightly linked product strategy in a specialized part of the drug industry.
Continue CU6 Research
Other Clarity Pharmaceuticals Ltd listings: